AKRO - Akero Therapeutics - Biotechnology

Summary

• 88% technical buy signals.
• 7 new highs and up 222.89% in the last month.
• Analyst's price targets from 30.00 to 62.00.

The Chart of the Day belongs to the health care company Akero Therapeutics ( AKRO ). I found the stock by sorting the Russell 3000 Index stocks first by the most gain in the last month and having a Trend Spotter buy signal then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter first signaled a buy on 8/24, the stock gained 187.78%.

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis ((NASH)) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin ((EFX)), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. (Source: Seeking Alpha)

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart Technical Indicators:

• 88% technical sell signals but increasing to buy
• Negative 22.36 Weighted Alpha
• 74.48% gain loss in the last year
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 7 new highs and up 222.89% in the last month
• Relative Strength Index 77.61%
• Technical support level at 37.14
• Recently traded at 38.05 with 50 day moving average of 20.38

Fundamental factors:

• Market Cap $1.42 billion
• Analysts have not given solid Revenue and Earnings projections

For further details see: